Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study.
Liz Van RossenAntoni ChanAnnie GilbertKarl GaffneyClaire HarrisPedro M MachadoLiliana R SantosAlice HeaneyPaul BassetAndrew KeatPublished in: Rheumatology advances in practice (2020)
Many patients with axSpA remain well symptomatically after stepping down the dose of TNF inhibitor, but young women are less likely to do well on a reduced dose. Dose reduction should be one element of the management of patients with axSpA.